In this Issue:
Erlotinib + bevacizumab maintenance for mCRC
BRAF inhibition with vemurafenib in mCRC
BRAF + MEK inhibition in mCRC
Better prognosis with high BMI in mCRC
RAS mutation testing before anti-EGFR mAb therapy
CDX2 as a prognostic biomarker in early CRC
Cognitive impairment in CRC
Genotype-guided dosing of fluoropyrimidine
Cytoreductive surgery with intraperitoneal chemotherapy
Please login below to download this issue (PDF)